Citeline Podcasts

Citeline places biopharma and medical device professionals, and those who focus on these industries, at the forefront of knowledge and insight, by providing the perfect combination of news and information together with penetrating insight and analysis. Citeline is a leader in the field of healthcare industry information.

Citeline Podcasts is a business podcast hosted by Unknown Host, with 0 episodes on record and a Required Pod Score of 80.

Unknown Host hosts Citeline Podcasts, a business show with 0 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Citeline Podcasts

  【3分で解説 #世界のファーマ】第31回　中国、バイオ医薬品の成長に本腰　初の5カ年計画 (Japanese-language podcast) Sept. 30, 2026

  Sep 30, 20263 min

  世界の製薬ビジネスを伝える「Scrip」と、各国で変化する製薬関連の規制に特化した「Pink Sheet」。普段は英語で発信する2つのオンラインメディアから、今注目の話題を日本語で短くまとめてお届けします。今回取り上げた記事はこちら Six Chinese Drugs On Course For Blockbuster Status As Five-Year Plan Sets The Bar https://insights.citeline.com/scrip/focus-on-asia/china/six-chinese-drugs-on-course-for-blockbuster-status-as-five-year-plan-sets-the-bar-KEBII2JIZNC7RIE2KMLCA2O4D4/ China Eyes Central Role On Global Biopharma Stage https://insights.citeline.com/pink-sheet/geography/asia/china/china-eyes-central-role-on-global-biopharma-stage-NWR3FDT5ZJBB3A53YZEGGJW7RI/ ※全文の閲覧には購読（有料）が必要です。世界の製薬ビジネスメディアScrip（スクリップ）とは？https://www.citeline.com/ja-jp/products-services/commercialization/scrip

  ListenShow Notes
• 

  Citeline Podcasts

  Strategic Intent: Boehringer Ingelheim's Brian Hilberdink on Launching Into the GLP-1 Era

  Sep 28, 202630 min

  Brian Hilberdink, President of US Human Pharma at Boehringer Ingelheim, joined Strategic Intent to talk about leading one of the company's most ambitious US launch periods in years, spanning a specialty drug in interstitial lung disease, an established franchise in cardiometabolic disease and a potential entry into the hyper-competitive obesity market. He discusses how private ownership shapes long-term decision-making, why he wants to reframe the obesity conversation away from the scale and toward metabolic health, how the payer landscape has fundamentally changed since he started in the industry, and what role AI will play in the future of commercialization.

  ListenShow Notes
• 

  Citeline Podcasts

  Drug Fix: Lessons From US FDA Commissioner Nominee Heidi Overton’s Confirmation Hearing

  Sep 25, 202630 min

  Pink Sheet Executive Editor Derrick Gingery, Senior Reporter Maaisha Osman, Senior Editor Sue Sutter and Editor-in-Chief Nielsen Hobbs dissect US Food and Drug Administration commissioner nominee Heidi Overton’s answers during her Senate confirmation hearing and dominant themes (:58), rate the potential for her confirmation (13:14), as well as consider her responses to particular controversial issues like mifepristone safety (16:06) and more practical issues like advisory committee meetings (21:23). They also look at the remaining hurdles for Overton’s bid to take control of the agency (24:40). More On These Topics From The Pink Sheet Overton Calls MMR Vaccine ‘Not Lethal,’ Defends Trump’s Claim As Outreach To Vaccine Skeptics: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/overton-calls-mmr-vaccine-not-lethal-defends-trumps-claim-as-outreach-to-vaccine-skeptics-TO3WNT3NUZGJ5IDRRUBDHF5CIA/ US FDA Commissioner Nominee Overton Says Adcomms ‘Critical,’ Hedges On Mifepristone Safety: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/us-fda-commissioner-nominee-overton-says-panels-are-critical-hedges-on-mifepristone-safety-RGSODPP5IRHLDA7A26TGOZ7LRI/ Former FDA Commissioners’ Backing May Help Overton Amid Stakeholder Opposition: https://insights.citeline.com/pink-sheet/agency-leadership/us-fda/former-fda-commissioners-backing-may-help-overton-amid-stakeholder-opposition-66MIFWT47ZDKDLYEFSBHMUEOEE/

  ListenShow Notes
• 

  Citeline Podcasts

  Strategic Intent: Rubedo’s Seno-Adaptive Bet On Longevity Medicine

  Sep 21, 202640 min

  In this episode of Strategic Intent, In Vivo senior reporter David Wild speaks with Frederick Beddingfield, CEO of Rubedo Life Sciences, about turning the biology of aging into real medicines. They discuss Rubedo’s lead topical GPX4 modulator RLS‑1496 in actinic keratosis, psoriasis, atopic dermatitis, and photo‑aged skin; a new push into androgenetic alopecia; and the company’s “seno-adaptive” approach to selectively clearing or rejuvenating aging cells. The conversation also explores Rubedo’s AI-enabled drug discovery platform, how dermatology can validate a broader longevity thesis, and what it will take for aging biology to become a credible, commercial drug category.

  ListenShow Notes
• 

  Citeline Podcasts

  Assessing the current dealmaking environment for psychedelic medicine.

  Sep 18, 202620 min

  Joseph Haas and Emma Wille overview the dealmaking environment for psychedelic medicine given recent developments in the space: Eli Lilly's $2.8 billion acquisition of AtaiBeckley in July, the imminent FDA filing of Compass Pathways' COMP360 for treatment-resistant depression and a more relaxed regulatory environment for psychedelic therapies under the current administration.

  ListenShow Notes

Recent guests on Citeline Podcasts. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.